Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ethinylestradiol/Chlormadinone Acetate is a safe and effective birth control pill that also helps regulate menstrual cycles, reduces period pain, and treats certain skin and hair conditions.

This review discusses the effects and selection criteria of different progestogens in various treatments but reports no direct clinical comparisons of their metabolic effects.

This study found that Polygoni multiflori Radix water extracts stimulated hair growth and hair follicle development in mice, suggesting it may be safer than minoxidil.

This study evaluated local treatment with minoxidil 2% watery solution in patients with androgenetic alopecia but did not report detailed clinical outcomes.

In this randomized, double-blind, placebo-controlled trial, topical 3% minoxidil was found to significantly improve facial hair density and diameter, quality of life, and patient satisfaction in transgender men on stable gender-affirming hormone therapy, with minimal adverse events compared to placebo.

Long-term use of finasteride may cause breast cancer in men.

This article discusses the MaasaLong male enhancement supplement, which claims to improve erectile dysfunction and overall male health but provides no new empirical results.

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

This study found that the penetration enhancer SEPA™ significantly increased both the speed and amount of hair growth from minoxidil in balding stumptail macaques compared to Rogaine®.

This study characterized the SARM PF-05314882, finding it demonstrates anabolic activity in rats with minimal effects on the prostate, seminal vesicles, and luteinizing hormone levels.

This study found that poly(propylene carbonate maleate) microspheres can successfully prolong finasteride release over 42 days, showing potential for long-term sustained drug delivery.

This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.

This study found that combining 7% chamomile extract with 5% minoxidil solution may reduce cutaneous side effects like itching, scaling, and erythema in male patients with androgenic alopecia, potentially improving treatment compliance.

This study developed a novel method to simultaneously measure finasteride, dutasteride, and related biomarkers in serum, finding that both drugs lowered DHT levels while increasing substrate concentrations.

This study found that surface-modified liquid crystalline nanoparticles significantly enhanced skin permeation of finasteride and dutasteride compared to unmodified nanoparticles, suggesting potential for improved treatment efficacy in androgenetic alopecia.

This study found that a multimodal microemulsion containing minoxidil, diclofenac, and tea tree oil was significantly more effective and stable than minoxidil alone in treating androgenic alopecia over a 32-week period.

In this self-controlled comparative study of 16 women with Female Pattern Hair Loss, MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced cases compared to standard Minoxidil treatment, though overall effectiveness was similar.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

In this study, researchers demonstrated that in a mouse model, the stimulation of mammary tumor growth due to progesterone is primarily caused by its metabolite, 5αP, not progesterone itself.

This research aims to evaluate 6-month changes in total and terminal hair density, with data quality assessed using Cochrane risk of bias tools, but does not report specific study results yet.

This study found that both sublingual and oral minoxidil at 5 mg per day increased hair density similarly in men with androgenetic alopecia over 24 weeks, but sublingual administration was associated with fewer palpitations.

In this study, the researchers found that the topical generic 5% new minoxidil foam is as effective and safe as the 5% Rogaine® foam in increasing hair density and diameter in men with androgenetic alopecia over 24 weeks.

This study found that using anhydrous cerium(III) chloride with alkyl Grignard reagents significantly improved the addition to sterically hindered 17-ketosteroids, resulting in high yields and stereoselectivity.

In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.

This study found that a newly developed peptide, FOL-005, significantly inhibited hair growth and counteracted minoxidil's effects in organ-cultured human male scalp skin and mouse models, without apparent toxicity.

This study reported that both drospirenone and chlormadinone acetate oral contraceptives had similar beneficial effects on clinical, metabolic, and hormonal parameters in women with polycystic ovary syndrome over six months.

In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

This study found that patients with androgenic alopecia had altered neuroactive steroid levels and depression symptoms after stopping finasteride treatment, suggesting lingering neuropsychiatric effects.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.